Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.

Cappuccini F, Pollock E, Stribbling S, Hill AVS, Redchenko I.

Oncotarget. 2017 Jul 18;8(29):47474-47489. doi: 10.18632/oncotarget.17666.

2.

The Human Vaccines Project: A roadmap for cancer vaccine development.

Romero P, Banchereau J, Bhardwaj N, Cockett M, Disis ML, Dranoff G, Gilboa E, Hammond SA, Hershberg R, Korman AJ, Kvistborg P, Melief C, Mellman I, Palucka AK, Redchenko I, Robins H, Sallusto F, Schenkelberg T, Schoenberger S, Sosman J, Türeci Ö, Van den Eynde B, Koff W, Coukos G.

Sci Transl Med. 2016 Apr 13;8(334):334ps9. doi: 10.1126/scitranslmed.aaf0685. Review.

PMID:
27075624
3.

Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer.

Cappuccini F, Stribbling S, Pollock E, Hill AV, Redchenko I.

Cancer Immunol Immunother. 2016 Jun;65(6):701-13. doi: 10.1007/s00262-016-1831-8. Epub 2016 Apr 6.

4.

Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.

Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Griffiths R, Steven N, Hawkins RE.

Cancer Immunol Immunother. 2008 Jul;57(7):977-86.

PMID:
18060404
5.

Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.

Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Melcher A, Nicholls J, Wassan H, Habib N, Anthoney A.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4487-94.

6.

Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.

Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, Ryan MG, Myers KA, Drury N, Kingsman SM, Hawkins RE, Carroll MW.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3416-24.

7.
8.

Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated.

Harrop R, Ryan MG, Myers KA, Redchenko I, Kingsman SM, Carroll MW.

Cancer Immunol Immunother. 2006 Sep;55(9):1081-90. Epub 2005 Nov 26.

PMID:
16311730
9.

Monitoring of human immunological responses to vaccinia virus.

Harrop R, Ryan MG, Golding H, Redchenko I, Carroll MW.

Methods Mol Biol. 2004;269:243-66. Review.

PMID:
15114020
10.

Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.

Leen A, Meij P, Redchenko I, Middeldorp J, Bloemena E, Rickinson A, Blake N.

J Virol. 2001 Sep;75(18):8649-59.

11.
12.

CD4+ T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis.

Wilson AD, Redchenko I, Williams NA, Morgan AJ.

Int Immunol. 1998 Aug;10(8):1149-57.

PMID:
9723701
13.

Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing.

Blake N, Lee S, Redchenko I, Thomas W, Steven N, Leese A, Steigerwald-Mullen P, Kurilla MG, Frappier L, Rickinson A.

Immunity. 1997 Dec;7(6):791-802.

14.

Inhibitory effect of calf fetuin on the cytotoxic activity of LAK cell-derived factors and tumor necrosis factor.

Chertov OYu, Ermolaeva MV, Satpaev DK, Saschenko LP, Kabanova OD, Lukanidin EM, Lukjianova TI, Redchenko IV, Blishchenko LYu, Gnuchev NV.

Immunol Lett. 1994 Sep;42(1-2):97-100.

PMID:
7530233
15.

Contribution of membrane-associated cytotoxic proteins to cytolysis of L929 and K562 target cells mediated by LAK cells with different phenotypes.

Saschenko LP, Gnuchev NV, Redchenko IV, Kabanova OD, Lukjianova TI, Blishchenko LYu, Satpaev DK, Chertov OYu.

Immunol Lett. 1994 Mar;39(3):243-7.

PMID:
8034339
16.

Time-dependent changes of LAK cell phenotypes correlate with the secretion of different cytotoxic proteins.

Sashchenko LP, Gnuchev NV, Lukjanova TI, Redchenko IV, Kabanova OD, Lukanidin EM, Blishchenko EYu, Satpaev DK, Khaidukov SV, Chertov OYu.

Immunol Lett. 1993 Aug;37(2-3):153-7.

PMID:
8258456
17.

[Functional changes in lymphokine-activated lymphocytes depending on the incubation time with interleukin-2].

Sashchenko LP, Gnuchev NV, Kabanova OD, Blishchenko EIu, Luk'ianova TI, Redchenko IV, Savtsova ZD, Chertov OIu, Lukanidin EM.

Dokl Akad Nauk. 1992;324(2):475-9. Russian. No abstract available.

PMID:
1451639
18.

[Vitamin E levels in the plasma of girls during puberty].

Redchenko IA.

Vopr Okhr Materin Det. 1972 May;17(5):87. Russian. No abstract available.

PMID:
5029762
19.

[Experimental data on interoception of the pregnant uterus].

REDCHENKO IA.

Akush Ginekol (Mosk). 1954 Jan-Feb;1:8-13. Undetermined Language. No abstract available.

PMID:
13138463

Supplemental Content

Loading ...
Support Center